The FDA has identified serious liver injuries among patients taking Tavneos, including fatal cases and a rare condition that destroys small bile ducts. The medicine, also called avacopan, treats severe active ANCA-associated vasculitis. Regulators advised monitoring and prompt evaluation rather than an automatic stop for every patient.
The safety communication was issued March 31, 2026. It added serious postmarketing cases to an existing liver-risk picture and reinforced the need for monitoring during treatment.
Tavneos treats inflammation that damages small blood vessels
ANCA-associated vasculitis is a group of autoimmune diseases in which inflammation injures small blood vessels, often affecting the kidneys, lungs and other organs. Tavneos blocks the C5a receptor, interrupting part of the complement immune pathway that recruits and activates inflammatory cells.
The drug can reduce reliance on high-dose glucocorticoids in a treatment plan that also includes other immunosuppressive therapy. That benefit must be weighed against infection, liver and disease-specific risks.
The new concern came from use after approval
In the FDA safety communication, regulators described seven serious postmarketing cases from Japan and Canada. Some involved fatal drug-induced liver injury, and some involved vanishing bile duct syndrome.
Premarket trials had already identified hepatotoxicity as a serious adverse reaction. The postmarketing pattern expanded the concern because fatal outcomes and progressive bile-duct loss represented a more severe form than the existing information fully conveyed.
Vanishing bile duct syndrome can cause lasting damage
Bile ducts carry bile from the liver. In vanishing bile duct syndrome, those small channels are progressively destroyed, slowing or blocking bile flow. The process can lead to jaundice, itching, fatigue and permanent liver injury.
Symptoms of drug-induced liver injury can also include dark urine, abdominal discomfort, nausea and loss of appetite. Symptoms are not specific, and some patients have abnormal laboratory tests before obvious illness appears.
Monitoring turns a warning into a clinical action
The FDA advised baseline and repeated liver testing, with urgent evaluation when symptoms or abnormal results appear. Clinicians may interrupt treatment while determining whether Tavneos is responsible and consider alternatives if injury does not improve.
The earlier prescribing information already instructed clinicians to monitor liver tests and described thresholds for interrupting therapy. The 2026 communication adds postmarketing evidence that raises the seriousness of unexplained abnormalities.
Patients should not stop an immune drug abruptly without guidance
Active vasculitis can damage organs quickly. A headline about liver risk does not establish that a particular symptom comes from Tavneos or that stopping immediately is safer than continuing until medical advice is available.
A prescribing team can interpret test results, disease activity and other possible causes such as infection, alcohol, supplements or another medicine. Severe symptoms, jaundice or rapidly worsening illness warrant urgent assessment.
Postmarketing evidence has limits and value
Seven cases cannot provide a precise rate because the number of exposed patients and reporting completeness are uncertain. Spontaneous reports can also contain confounding illnesses and drugs. That prevents a simple calculation of individual risk.
Rare, distinctive and severe patterns can still justify action. A regulator looks at timing, biological plausibility, dechallenge after stopping and whether alternative causes fit. Fatal outcomes lower the threshold for communicating a signal while fuller evidence develops.
The March 31 communication anchors what the agency knew and when it acted. Its safety information remains continuing guidance for clinicians and patients using Tavneos.
Underlying disease can complicate liver assessment
Patients with severe vasculitis often receive several medicines and may have systemic inflammation, infection or organ dysfunction. Those factors can change liver tests independently of Tavneos. Establishing drug-induced injury therefore requires a timeline, exclusion of other causes and observation after treatment changes.
A pattern involving bilirubin, alkaline phosphatase and aminotransferases can help clinicians characterize the injury. Imaging may be needed when bile-duct obstruction is possible, and specialist evaluation becomes important if tests do not improve.
Risk communication should preserve both severity and uncertainty
Fatal cases make the signal urgent, but the available reports do not show that serious injury is common. Stating both facts prevents two opposite errors: minimizing a potentially life-threatening reaction and implying that most patients face the same outcome.
Absolute risk may become clearer through exposure estimates, registry studies and label surveillance. Reports from different countries can also reveal whether genetics, dose, monitoring or prescribing patterns affect the signal.
The distinction between known adverse effects and newly characterized ones matters. General hepatotoxicity appeared in earlier labeling; fatal injury and vanishing bile duct syndrome made the postmarketing pattern more concerning. A good medication review should therefore use the most recent approved information, not only the label available when treatment began.
Patients and clinicians can also report suspected events through MedWatch. A well-documented report includes dates, doses, laboratory trends, other medicines and the response to stopping or restarting. Those details are more useful than a bare statement that an event occurred.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
